EGFR and acute myeloid leukemia: In future studies, it will be important to functionally characterize the role of high‐level ribosomal and ErbB cargo in EVs from AML cells during progression, therapeutic response and resistance development, which may open new avenues for efficient combination therapies with FLT3 and Hh pathway inhibitors.